Contribute Try STAT+ Today

A version of this digest first appeared in the weekly STAT Health Tech newsletter. To receive future editions, sign up here.

Let’s start with a briefing on rapid financial maneuvering right now in the telehealth industry, and the significant risks that underlie it.

To catch you up: The nation’s largest telehealth companies are making big bets on a surge in demand amid the Covid-19 pandemic. Teladoc, the largest provider, is acquiring the online chronic disease company Livongo in an $18.5 billion deal, and AmwellMDLive, and GoodRx — which operates a telehealth business called HeyDoctor — are all preparing for initial public offerings. The paperwork for those IPOs offer a new window into the long-murky picture of finances in telemedicine, as Rebecca explains in a new story that digs into the filings.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.